Safety and efficacy of valsartan versus enalapril in heart failure patients (Q44123601)

30 November 2017

title

Safety and efficacy of valsartan versus enalapril in heart failure patients (English)

1 reference

30 November 2017

0 references

1 reference

Ronnie Willenheimer

1

1 reference

30 November 2017

Claes Helmers

2

1 reference

30 November 2017

Emil Pantev

3

1 reference

30 November 2017

Erik Rydberg

4

1 reference

30 November 2017

Per Löfdahl

5

1 reference

30 November 2017

Allan Gordon

6

1 reference

30 November 2017

Heart Failure Valsartan Exercise Capacity Evaluation Study Group

7

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

International Journal of Cardiology

30 November 2017

published in

1 reference

30 November 2017

volume

85

1 reference

30 November 2017

issue

2-3

1 reference

30 November 2017

page(s)

261-270

1 reference

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Antihypertensive Therapy with MK 4211

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Angiotensin II-forming pathways in normal and failing human hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

ACE inhibitor use in heart failure: would that it were so

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Valsartan in heart failure patients previously untreated with an ACE inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) i

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Bradykinin B2-receptor activation augments norepinephrine exocytosis from cardiac sympathetic nerve endings. Mediation by autocrine/paracrine mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

The role of the endocardium in the facilitatory effect of bradykinin on electrically-induced release of noradrenaline in rat cardiac ventricle

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Bradykinin modulation of isolated rabbit heart function is mediated by intrinsic cardiac neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Receptors and their classification: focus on angiotensin II and the AT2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900154-7

7 January 2021

10.1016/S0167-5273(02)00154-7

Identifiers

DOI

1 reference

30 November 2017

1 reference